A comparison of Daunorubicin/Ara-C (DA) versus Daunorubicin/Clofarabine (DClo) and two versus three courses of total treatment for older patients with AML and high risk MDS: results of the UK NCRI AML16 Trial [Abstract]

Burnett, Alan Kenneth, Russell, Nigel H., Kell, Jonathan, Kjeldsen, Lars, Milligan, Donald, Cahalin, Paul and Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062 2012. A comparison of Daunorubicin/Ara-C (DA) versus Daunorubicin/Clofarabine (DClo) and two versus three courses of total treatment for older patients with AML and high risk MDS: results of the UK NCRI AML16 Trial [Abstract]. Blood -New York- 120 (21)

Full text not available from this repository.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General) R Medicine > RC Internal medicine R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Additional Information:	54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) Location: Atlanta, GA Date: DEC 08-11, 2012
Publisher:	American Society of Hematology
ISSN:	0006-4971
Last Modified:	24 Oct 2022 11:56
URI:	https://orca.cardiff.ac.uk/id/eprint/49805

Citation Data

Actions (repository staff only)

Edit Item

CORE (COnnecting REpositories)

CORE (COnnecting REpositories)

CORE (COnnecting REpositories)